CA
NZ
UK
AU
IND
US
• Monopar Therapeutics released new Phase 3 data for ALXN1840, showing improved neurologic and global clinical outcomes in Wilson disease patients.
• The new director will sit on key committees.
• Regenxbio earned a $100.0 million milestone from AbbVie Global Enterprises Ltd. Under their collaboration agreement.
• The company secures a revolving credit facility valued at $30.0 million
• Stryker (NYSE: SYK) consolidates orthopaedic instruments and Mako technologies into a new Ortho Tech business unit.
• Tonix Pharmaceuticals (NASDAQ: TNXP) initiated enrollment in its Phase 2 study for TNX-102 SL 5.6 mg as a first-line treatment option for major depressive disorder.
• Viridian Therapeutics (NASDAQ: VRDN) received FDA approval for Lumvoa, the first treatment for thyroid eye disease regardless of disease activity or duration.
• Beyond Air Inc. (NASDAQ: XAIR) released a statement detailing its financial performance for the most recent reporting period.
• The new role carries a fixed end date of March 31, 2027, unless terminated earlier by either party.
• Slide presentation for the investor call was filed as Exhibit 99.2.
Please wait processing your request...